Skip to main content

Advertisement

Springer Nature Link
Log in

Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Increasing evidence suggests that dysregulation of microRNAs is correlated with malignant transformation and tumor development. miR-100, a potential tumor suppressor, is downregulated by many human cancers. However, the expression and functions of miR-100 in hepatocellular carcinoma (HCC) are still unclear. The aim of this study was to detect the expression of miR-100 in HCC tissues and investigate its clinicopathological and prognostic significance. Also, the effects of miR-100 on growth and apoptosis of HCC cells and its potential molecular mechanisms were analyzed. Results showed that the expression level of miR-100 in HCC tissues was significantly lower than that in matched non-cancerous liver tissues. Also, low-miR-100 expression was observed to be significantly correlated with higher tumor grade, higher incidence of lymph node metastasis, advanced TNM stage and higher incidence of tumor recurrence in HCC patients. Multivariate survival analyses suggested that low-miR-100 expression was an independent prognostic factor for HCC patients (HR = 1.66, 95 % CI 1.32–2.82, P = 0.019). In addition, we found that upregulation of miR-100 could inhibit growth and increase apoptosis of HCC cells by downregulating polo-like kinase 1 (plk1). In HCC tissues, miR-100 expression was inversely correlated with the expression of plk1 protein (r = −0.418; P = 0.029). Therefore, downregulation of miR-100 was correlated with progressive pathological feature and poor prognosis in HCC patients, and miR-100 could function as a tumor suppressor by targeting plk1. miR-100 may serve as a prognostic marker and molecular therapeutic target in HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. McGlynn KA, London WT (2011) The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 15:223–243

    Article  PubMed  Google Scholar 

  2. Yuen MF, Hou JL, Chutaputti A et al (2009) Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24:346–353

    Article  PubMed  Google Scholar 

  3. Nelson P, Kiriakidou M, Sharma A et al (2003) The microRNA world: small is mighty. Trends Biochem Sci 28:534–540

    Article  PubMed  CAS  Google Scholar 

  4. Subramanian S, Steer CJ (2010) MicroRNAs as gatekeepers of apoptosis. J Cell Physiol 223:289–298

    PubMed  CAS  Google Scholar 

  5. Berardi E, Pues M, Thorrez L et al (2012) miRNAs in ESC differentiation. Am J Physiol Heart Circ Physiol 303:H931–H939

    Article  PubMed  CAS  Google Scholar 

  6. Roy S, Sen CK (2012) miRNA in wound inflammation and angiogenesis. Microcirculation 19:224–232

    Article  PubMed  CAS  Google Scholar 

  7. Jansson MD, Lund AH (2012) MicroRNA and cancer. Mol Oncol 6:590–610

    Article  PubMed  CAS  Google Scholar 

  8. Braconi C, Henry JC, Kogure T (2011) The role of microRNAs in human liver cancers. Semin Oncol 38:752–763

    Article  PubMed  CAS  Google Scholar 

  9. Negrini M, Gramantieri L, Sabbioni S et al (2011) microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 11:500–521

    Article  PubMed  CAS  Google Scholar 

  10. Oliveira JC, Brassesco MS, Morales AG et al (2011) MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev 12:3001–3004

    PubMed  Google Scholar 

  11. Liu J, Lu KH, Liu ZL et al (2012) MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer 12:519

    Article  PubMed  CAS  Google Scholar 

  12. Zheng YS, Zhang H, Zhang XJ et al (2012) MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 31:80–92

    Article  PubMed  Google Scholar 

  13. Petrelli A, Perra A, Schernhuber K et al (2012) Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an earlyevent maintained along tumor progression. Oncogene 31:4517–4526

    Article  PubMed  CAS  Google Scholar 

  14. Tovar V, Alsinet C, Villanueva A et al (2010) IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52:550–559

    Article  PubMed  CAS  Google Scholar 

  15. Shi W, Alajez NM, Bastianutto C et al (2010) Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer 126:2036–2048

    PubMed  CAS  Google Scholar 

  16. Peng DX, Luo M, Qiu LW et al (2012) Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 27:1238–1244

    PubMed  CAS  Google Scholar 

  17. Carthew RW (2006) Gene regulation by microRNAs. Curr Opin Genet Dev 16:203–208

    Article  PubMed  CAS  Google Scholar 

  18. Lee S, Vasudevan S (2013) Post-transcriptional stimulation of gene expression by microRNAs. Adv Exp Med Biol 768:97–126

    Article  PubMed  Google Scholar 

  19. Osman A (2012) MicroRNAs in health and disease–basic science and clinical applications. Clin Lab 58:393–402

    PubMed  CAS  Google Scholar 

  20. Roberts AP, Lewis AP, Jopling CL (2011) The role of microRNAs in viral infection. Prog Mol Biol Transl Sci 102:101–139

    Article  PubMed  CAS  Google Scholar 

  21. El Tayebi HM, Hosny KA, Esmat G et al (2012) MiR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett 586:3309–3316

    Article  PubMed  Google Scholar 

  22. Zhang L, Yang L, Liu X et al (2013) MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein through nuclear factor kappa B pathways. Hepatology 57:1919–1930

    Article  PubMed  CAS  Google Scholar 

  23. Zhang Y, Wei W, Cheng N et al (2012) Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 56:1631–1640

    Article  PubMed  CAS  Google Scholar 

  24. Zhang LY, Liu M, Li X et al (2013) miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem 288:4035–4047

    Article  PubMed  CAS  Google Scholar 

  25. Furuta M, Kozaki K, Tanimoto K et al (2013) The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One 8:e60155

    Article  PubMed  CAS  Google Scholar 

  26. Yau WL, Lam CS, Ng L et al (2013) Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process. PLoS One 8:e57882

    Article  PubMed  CAS  Google Scholar 

  27. Wang S, Xue S, Dai Y et al (2012) Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol 7:159

    Article  PubMed  Google Scholar 

  28. Wang G, Chen L, Meng J et al (2013) Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol 45:373–379

    Article  PubMed  CAS  Google Scholar 

  29. Liu XS, Song B, Liu X (2010) The substrates of Plk1, beyond the functions in mitosis. Protein Cell 1:999–1010

    Article  PubMed  CAS  Google Scholar 

  30. Pellegrino R, Calvisi DF, Ladu S et al (2010) Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 51:857–868

    PubMed  CAS  Google Scholar 

  31. He ZL, Zheng H, Lin H et al (2009) Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 15:4177–4182

    Article  PubMed  CAS  Google Scholar 

  32. He Z, Wu J, Dang H et al (2011) Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression. Cancer Lett 303:92–98

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Thanks to the sincere help and technical support by the department of biochemistry and molecular biology in Xi’an Jiao Tong University.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The First People’s Hospital of Yancheng, The Fourth Affiliated Hospital, Medical School of Nantong University, No. 14 Yuehe Road, Tinghu District, Yancheng, 224001, Jiangsu, People’s Republic of China

    Ping Chen, Xia Zhao & Liang Ma

Authors
  1. Ping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xia Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping Chen.

Additional information

P. Chen and X. Zhao should be regarded as joint first authors for their equal contributions.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, P., Zhao, X. & Ma, L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem 383, 49–58 (2013). https://doi.org/10.1007/s11010-013-1753-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-013-1753-0

Keywords

Search

Navigation